Literature DB >> 28409896

Childhood osteosarcoma: Incidence and survival in Argentina. Report from the National Pediatric Cancer Registry, ROHA Network 2000-2013.

F Moreno1, W Cacciavillano2, M Cipolla1, M Coirini3, P Streitenberger4, J López Martí1, M Palladino2, M Morici5, M Onoratelli2, G Drago6, A Schifino3, M Cores7, A Rose2, J Jotomliansky3, M Varel8, M García Lombardi7.   

Abstract

BACKGROUND: Differences in incidence and survival in osteosarcoma reports are considerable worldwide.
PURPOSE: This study describes the incidence and survival of patients with osteosarcoma in Argentina with data from the National Pediatric Cancer Registry (ROHA), and the impact of age, gender, stage, regional, and socioeconomic indicators on outcome.
METHODS: Pediatric patients with osteosarcoma reported to ROHA from 2000 through 2013 were analyzed, the annual age-standardized incidence rate (ASR) was calculated using the National Vital Statistics, and survival was estimated. The extended human development index (EHDI) for each reporting region was used as an indicator of socioeconomic status.
RESULTS: There were 515 cases of osteosarcoma identified, yielding an ASR of 3.2/1,000,000 children (0-14 years old). The ASR did not vary significantly by year of diagnosis but ranged from 4.0/1,000,000 in the Cuyo/Western Central region to 2.7/1,000,000 in the northeast region (P < 0.000). The estimated 5-year survival rate was 45% (95% confidence interval [CI] 44-51%), with no difference by sex, diagnosis year, region, or EHDI score (P > 0.1 in all cases). Survival rate for localized disease was 52% (95% CI 45-57%) and for metastatic 22% (95% CI 15-30%).
CONCLUSIONS: In Argentina, ASR of osteosarcoma is similar to that in high-income countries, but survival is lower in all regions. Future work will focus on identification and reduction of causes of preventable treatment failure.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  Argentina; children; incidence; osteosarcoma; survival

Mesh:

Year:  2017        PMID: 28409896     DOI: 10.1002/pbc.26533

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  16 in total

1.  Factors Affecting Prognosis and Survival in Extremity Osteosarcoma.

Authors:  Anvesh Dharanikota; Ravi Arjunan; Ashwathappa Dasappa
Journal:  Indian J Surg Oncol       Date:  2021-01-06

2.  Transcriptomic analyses reveal the underlying pro-malignant functions of PTHR1 for osteosarcoma via activation of Wnt and angiogenesis pathways.

Authors:  Shenglong Li; Yujin Dong; Ke Wang; Zhe Wang; Xiaojing Zhang
Journal:  J Orthop Surg Res       Date:  2017-11-09       Impact factor: 2.359

3.  PARK2 inhibits osteosarcoma cell growth through the JAK2/STAT3/VEGF signaling pathway.

Authors:  Zhong Lei; Huijie Duan; Tengfei Zhao; Yuxiang Zhang; Guoqi Li; Jiahong Meng; Suzhan Zhang; Weiqi Yan
Journal:  Cell Death Dis       Date:  2018-03-07       Impact factor: 8.469

4.  Treatment-Related Prognostic Factors in Managing Osteosarcoma around the Knee with Limb Salvage Surgery: A Lesson from a Long-Term Follow-Up Study.

Authors:  Jianping Hu; Chunlin Zhang; Kunpeng Zhu; Lei Zhang; Tao Cai; Taicheng Zhan; Xiong Luo
Journal:  Biomed Res Int       Date:  2019-05-02       Impact factor: 3.411

5.  SHOX CNE9/10 Knockout in U2OS Osteosarcoma Cells and Its Effects on Cell Growth and Apoptosis.

Authors:  Xue-Jiao Xu; Shi-Jie Xin; Hui-Ying Mao; Hui-Jiao Zhang; Lan-Ni Chen; Li Li; Hua-Lei Bai; Hai-Hua Huang; Min Shu
Journal:  Med Sci Monit       Date:  2020-02-07

6.  Establishment of immune prognostic signature and analysis of prospective molecular mechanisms in childhood osteosarcoma patients.

Authors:  Zide Zhang; Chong Liu; Tuo Liang; Chaojie Yu; Zhaojie Qin; Xin Zhou; Jiang Xue; Haopeng Zeng; Zhaojun Lu; Guoyong Xu; Zequn Wang; Jiarui Chen; Jie Jiang; Xinli Zhan
Journal:  Medicine (Baltimore)       Date:  2020-11-13       Impact factor: 1.889

7.  PLOD1 Is a Prognostic Biomarker and Mediator of Proliferation and Invasion in Osteosarcoma.

Authors:  Haoli Jiang; Wei Guo; Shanyou Yuan; Lixia Song
Journal:  Biomed Res Int       Date:  2020-10-19       Impact factor: 3.411

8.  The Na+/K+ ATPase Inhibitor Ouabain Attenuates Stemness and Chemoresistance of Osteosarcoma Cells.

Authors:  Weixiong Guo; Bo Wei; Tingting Cheng; Xiaotao Xu; Feiling Ruan; Min Xiang
Journal:  Med Sci Monit       Date:  2019-12-11

9.  MicroRNA-99b predicts clinical outcome of osteosarcoma and suppresses tumor cell proliferation, migration and invasion.

Authors:  Xin Shi; Xingfa Guan
Journal:  Diagn Pathol       Date:  2019-10-24       Impact factor: 2.644

10.  Mangiferin suppresses human metastatic osteosarcoma cell growth by down-regulating the expression of metalloproteinases-1/2 and parathyroid hormone receptor 1.

Authors:  Jifeng Wen; Yong Qin; Chao Li; Xiankui Dai; Tong Wu; Wenzhe Yin
Journal:  AMB Express       Date:  2020-01-18       Impact factor: 3.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.